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In vitro antibacterial activity;
Methionyl-tRNA synthetase;
Molecular modellingAbstract As part of our ongoing research efforts to develop new antibacterial agents acting on
novel molecular targets, a series of twenty-two adenine and benzimidazole-based mimics of the lead
compound REP-3123 was designed to target methionyl-tRNA synthetase of Clostridium difﬁcile
and Bacillus anthracis based on a homology model. Structures of the target compounds were eluci-
dated by means of 1H and 13C NMR spectral data and their purity was confirmed by HRMS or
microanalyses. The target compounds were tested for their in vitro antibacterial activity against
those two challenging organisms by the microdilution method in brain heart infusion broth. Unfor-
tunately, six of the target compounds were not biologically tested due to inadequate solubility in
DMSO under the assay conditions. Only the fluoro-substituted adenine-based sulfamide (18)
showed activity against C. difﬁcile with an MIC of 85.33 lg/mL. The adenine-based thiourea
(32) and diamine (36) were the most promising antibacterial agents against B. anthracis with an
MIC of 92.16 lg/mL. The rest of the tested compounds either showed inferior activity
(MIC = 102.4 lg/mL) or were totally inactive. Although the compounds were not very active,
the biological data are employed as a basis for our currently underway investigation for structure
optimization.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
198 A.G. Eissa et al.1. Introduction
The recognition of Clostridium difﬁcile as an urgent threat to
human health in 2013 CDC report and the potential use of
Bacillus anthracis as a bioterrorist weapon, have accelerated
medicinal chemistry efforts to search new antibacterial agents
for those challenging organisms.1–3 C. difﬁcile is the most com-
mon cause of healthcare facility acquired diarrhoea. Improper
use of broad-spectrum antibiotics results in disturbance in the
healthy gut microbiome leading to colonization of C. difﬁcile
and emergence of gastrointestinal disorders.2 C. difﬁcile infec-
tion (CDI) can also now be found more commonly outside
healthcare facilities and in previously low-risk groups, such
as children, pregnant women and individuals with irritable
bowel syndrome.4 Recently CDI has exceeded MRSA as the
most common healthcare facility-associated infection.5 First-
line treatment of C. difﬁcile infections is usually metronidazole
for mild to moderate infection or vancomycin for moderate to
severe cases. Both drugs, however, do not effectively treat the
infection or prevent relapsing infection.6–8
B. anthracis, the causative agent of Anthrax, is a Gram-
positive rod sporulating bacteria that exists in the environment
as spores. B. anthracis spores are stable for long periods and
can remain viable in the soil for decades and grazing animals
are their usual host.9 Anthrax is a well-known zoonotic disease
around the world that can infect humans as well as most ani-
mals, especially grazing animals. Normally, human infections
may result from contact with infected animals or products,
such as hides or wool from infected animals.10 Anthrax can
be highly lethal. Although the disease has been well studied
since the nineteenth century, it has witnessed a renewed inter-
est during the past decade. However, due to two recent out-
breaks related to use as a bioterrorist agent in the USA
through contaminated mail and heroin in UK and Europe,
concerns over Anthrax have greatly increased.11,12 The current
vaccines are safe and effective but have limitations that justify
the need for the development of new antimicrobial agents
active against B. anthracis infections. The front-line antibiotics
recommended for the treatment of Anthrax are ciprofloxacin,
doxycycline and the b-lactams. However, B. anthracis strains
are increasingly becoming resistant to the current generation
of antibiotics.3
The steadily increasing incidence of bacterial resistance
necessitates the continuous search for new antibacterial agents
acting at novel molecular targets. Aminoacyl-tRNA syn-
thetases represent a family of enzymes that are essential for
protein biosynthesis. The development of the topical antibiotic
mupirocin, which acts by inhibition of isoleucyl-tRNA syn-
thetase, clinically validated this class of enzymes. In the past









Figure 1 Chemical structure of the lead compound REP-3123.get bacterial methionyl-tRNA synthetase that led to the dis-
covery of a few lead compounds. So far, REP-3123 (Fig. 1),
a novel diaryldiamine, is the only documented selective C. dif-
ﬁcile methionyl-tRNA synthetase inhibitor that has good
in vitro activity and selectivity against C. difﬁcile with no activ-
ity against other anaerobes that compromise the intestinal
flora.13,14 In addition, REP3123 demonstrated superior
in vivo efficacy compared to vancomycin in the hamster GI
infection model.15 On this basis, this particular lead compound
was taken as a template for the design of target compounds
previously reported by us.16 In the present investigation, we
continue our efforts to explore structural determinants of the
antibacterial activity of this novel lead compound.
To date, there is no reported crystal structure of C. difﬁcile
methionyl-tRNA synthetase. However, a homology model
previously prepared was reported describing the active site to
be formed of two pockets. Ile12, Asp51, Ala230 and Trp227
were the main residues of pocket 1 which is the methionine
binding pocket, while Glu55, Ser133 and Tyr225 formed an
adjacent pocket (pocket 2) with Lys56 bridging the two pock-
ets.17,18 Since methionyl tRNA synthetase enzyme sequences
for C. difﬁcile and B. anthracis19 were found to display a high
percentage identity (53.7%) and a high percentage similarity
(79.1%),20 our target compounds were tested against both
organisms for in vitro antibacterial activity.
2. Materials and methods
2.1. Chemistry
Melting points were determined using a Gallenkamp melting
point apparatus and were uncorrected. 1H and 13C-NMR spec-
tra were recorded on a Bruker Advance DP500 spectrometer
operating at 500 MHz and 125 MHz, respectively. NMR sol-
vents were chloroform-d (CDCl3), methanol-d4 (CD3OD),
and DMSO-d6 ((CD3)2SO). Chemical shifts are given in parts
per million (ppm) relative to the internal standard tetramethyl-
silane (Me4Si). Coupling constants (J-value) were calculated in
hertz (Hz). Microanalysis data were obtained by MEDAC Ltd,
Alpha 319, Chobham Business Centre, Chertsey Road, Chob-
ham, Surrey, UK. For column chromatography, a glass col-
umn was slurry packed in the appropriate eluent with silica
gel (Fluka Kieselgel 60), flash column chromatography was
performed with the aid of a bellow. Analytical thin layer chro-
matography (TLC) was carried out on precoated silica plates
(ALUGRAM SIL G/UV254) with visualization via UV light
(254 nm) and/or iodine stains.
2.1.1. tert-Butyl (2-bromoethyl)carbamate (1)
To a stirred and cooled (0 C) solution of 2-bromoethylamine
hydrobromide (10.0 g, 48.8 mmol) and triethylamine (13.6 mL,
97.6 mmol) in methanol (200 mL), was added di-tert-butyl
dicarbonate (16.0 g, 73.2 mmol). The mixture was stirred at
60 C for 1 h and then overnight at room temperature. The
mixture was concentrated under vacuum and dissolved in
dichloromethane (200 mL), then washed with 1 M aqueous
HCl (2  100 mL) and brine (2  100 mL). The organic layer
was dried over anhydrous MgSO4 and concentrated under vac-
uum to afford the title compound as colourless oil.21
Yield: 81%. 1H NMR (CDCl3) d: 5.09 (bs, 1H, NH), 3.49
(m, 2H, CH2), 3.41 (m, 2H, CH2), 1.41 (s, 9H, tert-butyl).
Adenine and benzimidazole-based mimics of REP-3123 as antibacterial agents 19913C NMR (CDCl3) d: 155.60 (C-ester), 79.81 (C-tert-butyl),
42.37 (CH2), 32.76 (CH2), 28.34 (3  CH3). The compound
was used without further characterization for the synthesis of
compounds (2,3).
2.1.2. General procedure for the synthesis of tert-butyl [2-
(adenyl or benzimidazolyl)ethyl]carbamate (2,3)
To a suspension of adenine or benzimidazole (5.65 mmol),
potassium carbonate (1.56 g, 11.30 mmol), and 18 crown 6
(0.15 g, 0.56 mmol) in anhydrous DMF (30 mL) was added
(2-bromoethyl)carbamic acid tert-butyl ester (1; 2.50 g,
11.16 mmol). The suspension was then stirred at 60 C over-
night. The reaction mixture was allowed to cool to room tem-
perature and inorganics removed by filtration, the filtrate was
concentrated under vacuum. The residue was dissolved in ethyl
acetate (100 mL) and washed with water (3  50 mL). The
organic layer was dried over anhydrous MgSO4 and concen-
trated under vacuum. The product was purified by recrystal-
lization from methanol to give the title compounds as white
crystals.
2.1.2.1. tert-Butyl (2-(6-amino-9H-purin-9-yl)ethyl)carbamate
(2). Yield: 92%. MP (C): 203–208 (lit. 181 C).21 1H NMR
(DMSO-d6) d: 8.14 (s, 1H, CH-Ar), 8.01 (s, 1H, CH-Ar), 7.15
(s, 2H, NH2), 6.94 (t, J= 5.3, 1H, NH), 4.18 (t, J= 5.8, 2H,
CH2), 3.34 (CH2, masked by H2O), 1.32 (s, 9H, tert-butyl).
13C NMR (DMSO-d6) d: 155.88 (C-ester), 155.52 (C-Ar),
152.22 (CH-Ar), 149.67 (C-Ar), 140.83 (CH-Ar), 118.74 (C-
Ar), 77.77 (C-tert-butyl), 42.76 (CH2), 39.00 (CH2), 28.10
(3  CH3, tert-butyl). The compound was used without further
characterization for the synthesis of compound (4).
2.1.2.2. tert-Butyl (2-(1H-benzimidazol-1-yl)ethyl)carbamate
(3). Yield: 80%. MP (C): 121–126. 1H NMR (DMSO-d6) d:
8.12 (s, 1H, CH-imidazole), 7.64 (d, J= 7.9, 1H, CH-Ar),
7.57 (d, J= 7.9, 1H, CH-Ar), 7.25 (t, J= 8.1, 1H, CH-Ar),
7.19 (t, J= 8.0, 1H, CH-Ar), 6.98 (t, J= 5.0, 1H, NH),
4.29 (t, J= 5.9, 2H, CH2), 3.31–3.34 (q, J= 5.9, 2H, CH2),
1.32 (s, 9H, 3  CH3-tert-butyl). 13C NMR (DMSO-d6) d:
155.59 (C-ester), 143.96 (C-imidazole), 143.36 (C-Ar), 134.10
(C-Ar), 122.11 (CH-Ar), 121.29 (CH-Ar), 119.32 (CH-Ar),
110.17 (CH-Ar), 77.82 (C-tert-butyl), 43.56 (CH2), 39.69
(CH2), 28.09 (3  CH3-tert-butyl). HRMS (EI): Calcd for
261.1477 [M]+, Found: 261.1476 [M]+. The compound was
used for the synthesis of compound (5).
2.1.3. General procedure for the synthesis of 9-(2-aminoethyl)-
9H-purin-6-amine triﬂuoroacetate (4) and 2-(1H-benzimidazol-
1-yl)ethanamine triﬂuoroacetate (4,5)
A solution of tert-butyl(2-(6-amino-9H-purin-9-yl)ethyl)carba
mate (2; 2.0 mmol) or tert-butyl (2-(1H-benzimidazol-1-yl)eth
yl)carbamate (3; 2.0 mmol) in trifluoroacetic acid/dichloro-
methane (20 mL, 75:25 v/v) was stirred overnight at room tem-
perature. The solvent was then co-evaporated with ethanol
several times. The residue was saturated with diethyl ether
(75 mL), stirred for 2 h to afford the title compounds as white
solids collected by filtration.
2.1.3.1. 9-(2-aminoethyl)-9H-purin-6-amine triﬂuoroacetate
(4). Yield: 94%. MP (C): 158–163 (lit. 139 C).21 1H NMR
(CD3OD) d: 8.40 (s, 1H, CH-Ar), 8.30 (s, 1H, CH-Ar), 4.65(t, J= 5.9, 2H, CH2), 3.55 (t, J= 5.9, 2H, CH2).
13C NMR
(CD3OD) d: 152.97 (C-Ar), 150.93 (C-Ar), 147.02 (CH-Ar),
145.00 (CH-Ar), 120.19 (C-Ar), 43.12 (CH2), 40.31 (CH2).
The compound was used without further characterization for
the synthesis of the final target sulfamides (13–19).
2.1.3.2. 2-(1H-benzimidazol-1-yl)ethanamine triﬂuoroacetate
(5). Yield: quantitative. MP (C): 214–219 (lit. 215–217 C).
1H NMR (DMSO-d6) d: 9.03 (s, 1H, CH-imidazole), 8.15 (s,
3H, NH3
+, exchangeable), 7.90 (d, J= 8.0, 1H, CH-Ar),
7.84 (d, J= 7.5, 1H, CH-Ar), 7.47–7.54 (m, 2H, CH-Ar),
4.67 (t, J= 6.1, 2H, CH2), 3.40 (t, J= 5.9, 2H, CH2).
13C
NMR (DMSO-d6) d: 143.96 (CH-imidazole), 143.80 (C),
135.15 (C), 123.11 (CH-Ar), 122.74 (CH-Ar), 120.45 (CH-
Ar), 111.13 (CH-Ar), 43.56 (CH2), 39.69 (CH2). The com-
pound was used without further characterization for the syn-
thesis of the final target sulfamides (20–25).
2.1.4. General procedure for the synthesis of N-(un)substituted-
benzyl-2-oxooxazolidine-3-sulfonamides (6–12)
To a flask filled with dichloromethane (7.60 mL) under nitro-
gen, was added chlorosulphonyl isocyanate (0.5 mL,
5.74 mmol) at room temperature. The reaction mixture was
cooled to about 0 C and a solution of 2-bromoethanol
(0.41 mL, 5.78 mmol) in dichloromethane (2.5 mL) was added
dropwise while maintaining the temperature between 0 and
10 C. The reaction mixture was stirred at the same tempera-
ture for 1 h. A mixture of the appropriate benzylamine
(6.32 mmol) and triethylamine (2.0 mL, 14.40 mmol) in
dichloromethane (5.5 mL) was then added dropwise while
maintaining the temperature between 0 and 10 C. The reaction
mixture was then allowed to reach room temperature. 0.2 M
aqueous HCl (100 mL) was then added and pH of the reaction
was adjusted to 2 with concentrated HCl if necessary. The reac-
tion mixture was decanted and the separated organic layer
washed with 0.2 M aqueous HCl (100 mL) and then with water
(100 mL). The organic layer was diluted with 100 mLwater and
as much as possible of dichloromethane was removed under
vacuum at a temperature below 25 C. The resulting suspension
was stirred for 2.5 h at room temperature, filtered, rinsed twice
with sufficient water and dried under vacuum at 60 C over-
night to afford the title compounds as white solids.
2.1.4.1. N-benzyl-2-oxooxazolidine-3-sulfonamide (6). Yield:
50%. MP (C): 144–147 (lit. 134–138 C).22 1H NMR
(DMSO-d6) d: 8.96 (t, J= 6.0, 1H, NH), 7.29–7.38 (m, 5H,
5  CH-Ar), 4.24 (d, J= 6.1, 2H, CH2-benzylic), 4.16 (dd,
J= 7.6, 9.1, 2H, CH2), 3.78 (dd, J= 6.7, 8.1, 2H, CH2).
13C
NMR (DMSO-d6) d: 152.35 (C), 137.28 (C), 128.36 (2  CH),
127.57 (2  CH), 127.42 (CH), 62.24 (CH2), 46.34 (CH2),
45.07 (CH2). The compound was used without further charac-
terization for the synthesis of the target sulfamides (13,20).
2.1.4.2. N-(4-methoxybenzyl)-2-oxooxazolidine-3-sulfonamide
(7). Yield: 60%. MP (C): 108–112. 1H NMR (DMSO-d6) d:
8.86 (t, J= 6.1, 1H, NH), 7.26 (d, J= 8.7, 2H, 2  CH-Ar),
6.92 (d, J= 8.7, 2H, 2  CH-Ar), 4.18 (dd, J= 7.6, 9.2, 2H,
CH2), 4.16 (d, J= 6.1, 2H, CH2-benzylic), 3.79 (dd, J= 6.6,
8.1, 2H, CH2), 3.75 (s, 3H, CH3).
13C NMR (DMSO-d6) d:
158.67 (C), 152.35 (C), 129.10 (C), 128.98 (2  CH), 113.75
(2  CH), 62.23 (CH2), 55.09 (CH3), 45.86 (CH2), 45.06
200 A.G. Eissa et al.(CH2). The compound was used without further characteriza-
tion for the synthesis of the target sulfamides (14,21).
2.1.4.3. N-(3-chlorobenzyl)-2-oxooxazolidine-3-sulfonamide
(8). Yield: 74%. MP (C): 102–108. 1H NMR (DMSO-d6) d:
9.02 (t, J= 6.1, 1H, NH), 7.31–7.42 (m, 4H, 4  CH-Ar),
4.24 (m, 4H, CH2- benzylic and CH2), 3.85 (dd, J= 6.7, 8.1,
2H, CH2).
13C NMR (DMSO-d6) d: 152.36 (C), 139.96 (C),
133.03 (C), 130.23 (CH), 127.37 (CH), 127.33 (CH), 126.20
(CH), 62.35 (CH2), 45.60 (CH2), 45.18 (CH2). HRMS m/z
(EI): Calcd for 289.0044 [MH], Found: 289.0040 [MH].
The compound was used for the synthesis of the target sul-
famides (15,22).
2.1.4.4. N-(2,4-dichlorobenzyl)-2-oxooxazolidine-3-sulfonamide
(9). Yield: 57%. MP (C): 136–142. 1H NMR (DMSO-d6) d:
9.02 (t, J= 5.9, 1H, NH), 7.63 (d, J= 2.0, 1H, CH-Ar),
7.52 (d, J= 8.4, 1H, CH-Ar), 7.48 (dd, J= 2.0, 8.4, 1H,
CH-Ar), 4.34 (m, 4H, 2  CH2), 3.93 (dd, J= 7.6, 8.9, 2H,
CH2).
13C NMR (DMSO-d6) d: 152.55 (C), 133.93 (C),
133.06 (C), 132.89 (C), 131.00 (CH), 128.65 (CH), 127.41
(CH), 62.47 (CH2), 45.28 (CH2), 43.46 (CH2). HRMS m/z
(EI): Calcd for 342.0077 [M+NH4]
+, Found: 342.0075 [M
+NH4]
+. The compound was used for the synthesis of the tar-
get sulfamides (16,23).
2.1.4.5. N-(3,4-dichlorobenzyl)-2-oxooxazolidine-3-sulfonamide
(10). Yield: 76%. MP (C): 123–128. 1H NMR (DMSO-d6) d:
9.04 (s, 1H, NH), 7.63 (d, J= 8.3, 1H, CH-Ar), 7.61 (d,
J= 1.7, 1H, CH-Ar), 7.34 (dd, J= 1.7, 8.3, 1H, CH-Ar),
4.27 (m, 4H, 2  CH2), 3.88 (m, 2H, CH2). 13C NMR
(DMSO-d6) d: 152.38 (C), 138.71 (C), 130.93 (C), 130.32
(CH), 129.95 (C), 129.52 (CH), 127.87 (CH), 62.41 (CH2),
45.24 (CH2), 44.99 (CH2). The compound was used without
further characterization for the synthesis of the target sul-
famides (17,24).
2.1.4.6. N-(4-ﬂuorobenzyl)-2-oxooxazolidine-3-sulfonamide
(11). Yield: 53%. MP (C): 112–116. 1H NMR (DMSO-d6)
d: 8.95 (t, J= 6.1, 1H, NH), 7.39 (m, 2H, CH-Ar), 7.19 (m,
2H, CH-Ar), 4.23 (m, 4H, 2  CH2), 3.84 (wt, J= 8.1, 7.7,
2H, CH2). The compound was used without further character-
ization for the synthesis of the target sulfamides (18,25).
2.1.4.7. N-(4-cyanobenzyl)-2-oxooxazolidine-3-sulfonamide
(12). Yield: 89%. MP (C): 160–164. 1H NMR (DMSO-d6)
d: 9.14 (t, J= 6.2, 1H, NH), 7.84 (d, J= 8.2, 2H, CH-Ar),
7.54 (d, J= 8.15, 2H, CH-Ar), 4.33 (d, J= 6.2, 2H, CH2),
4.26 (wt, J= 7.5, 8.2, 2H, CH2), 3.85 (wt, J= 7.5, 8.2, 2H,
CH2).
13C NMR (DMSO-d6) d: 152.43 (C), 143.31 (C),
132.31 (2  CH), 128.32 (2  CH), 118.75 (C), 110.11 (C),
62.42 (CH2), 45.73 (CH2), 45.22 (CH2). HRMS m/z (EI): Calcd
for 280.0392 [MH], Found: 280.0379 [MH]. The com-
pound was used for the synthesis of the target sulfamide (19).2.1.5. General procedure for the synthesis of N-[2-(adenyl- or
benzimidazolyl)ethyl]-N0-(un)substitutedbenzylsulfamides (13–
25)
To a suspension of 9-(2-aminoethyl)-9H-purin-6-amine trifluo-
roacetate (4; 1 eq.) or 2-(1H-benzimidazol-1-yl)ethanamine tri-
fluoroacetate (5; 1 eq.) in anhydrous acetonitrile (10 mL) wasadded triethylamine (3.3 eq.) followed by the appropriate N-
benzyl-2-oxooxazolidine-3-sulfonamide derivative (6–12;
1.1 eq.). The reaction was then stirred at 90 C overnight.
The reaction mixture was allowed to cool to room temperature
and water (100 mL) was slowly added. Acetonitrile was
removed under vacuum below 40 C. The resulting suspension
was stirred at room temperature for 2 h before it was collected
by filtration to afford the title compounds white solids. The
products were purified by recrystallization from methanol.
2.1.5.1. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-benzylsul-
famide (13). Yield: 37%. MP (C): 188–190. 1H NMR
(DMSO-d6) d: 8.16 (s, 1H, CH), 8.06 (s, 1H, CH), 7.43 (app.
s, 1H, NH), 7.20–7.27 (m, 8H, 5  CH-Ar, NH2, NH), 4.26
(app.s, 2H, CH2), 3.87 (app.s, 2H, CH2), 3.29 (app.s, 2H,
CH2).
13C NMR (DMSO-d6) d: 155.94 (C), 152.31 (CH),
149.52 (C), 141.05 (CH), 138.15 (C), 128.14 (2  CH), 127.60
(2  CH), 126.97 (CH), 118.80 (C), 45.65 (CH2), 42.76
(CH2), 41.58 (CH2). HRMS m/z (EI): Calcd for 348.1237 [M
+H]+, Found 348.1237 [M+H]+.
2.1.5.2. N-[2-(6-amino-9H-purin-9-yl)]-N0-(4-methoxyben-
zyl)sulfamide (14). Yield: 50%. MP (C): 186–188. 1H NMR
(DMSO-d6) d: 8.16 (s, 1H, CH), 8.06 (s, 1H, CH), 7.34 (t,
J= 5.5, 1H, NH), 7.22 (s, 2H, NH2), 7.17 (d, J= 7.9, 3H,
2  CH-Ar, NH), 6.86 (d, J= 8.3, 2H, 2  CH-Ar), 4.25 (t,
J= 5.5, 2H, CH2), 3.80 (d, J= 5.6, 2H, CH2), 3.73 (s, 3H,
CH3), 3.27 (d, J= 4.8, 2H, CH2).
13C NMR (DMSO-d6) d:
158.36 (C), 155.94 (C), 152.33 (CH), 149.51 (C), 141.08
(CH), 129.98 (C), 128.96 (2  CH), 118.78 (C), 113.57
(2  CH), 55.02 (CH3), 45.15 (CH2), 42.75 (CH2), 41.57




zyl)sulfamide (15). Yield: 15%. MP (C): 182–184. 1H NMR
(DMSO-d6) d: 8.15 (s, 1H, CH), 8.07 (s, 1H, CH), 7.52 (t,
J= 6.4, 1H, NH), 7.19–7.35 (m, 7H, NH, NH2, 4  CH-
Ar), 4.25 (t, J= 6.0, 2H, CH2), 3.89 (d, J= 6.4, 2H, CH2),
3.29 (q, J= 6.0, 2H, CH2).
13C NMR (DMSO-d6) d: 155.94
(C), 152.33 (CH), 149.53 (C), 141.06 (CH), 140.94 (C),
132.86 (C), 130.03 (CH), 127.31 (CH), 126.91 (CH), 126.17
(CH), 118.79 (C), 44.95 (CH2), 42.80 (CH2), 41.55 (CH2).
HRMS m/z (EI): Calcd for 382.0847 [M+H]+, Found:
382.0850 [M+H]+.
2.1.5.4. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-(2,4-
dichlorobenzyl)sulfamide (16). Yield: 45%. MP (C): 164–
168. 1H NMR (DMSO-d6) d: 8.15 (s, 1H, CH), 8.07 (s, 1H,
CH), 7.50 (m, 2H, NH+ CH-Ar), 7.49 (d, J= 8.4, CH-Ar),
7.43(dd, J= 1.7, 8.4, 1H, CH-Ar), 7.34 (t, J= 5.75, 1H,
NH), 7.19 (s, 2H, NH2, ex), 4.2 (t, J= 5.9, 2H, CH2), 3.9
(d, J= 5.9, 2H, CH2), 3.31 (m, 2H, CH2).
13C NMR
(DMSO-d6) d: 155.94 (C), 152.31 (CH), 149.52 (C), 141.01
(CH), 134.77 (C), 132.86 (C), 132.37 (C), 130.72 (CH),
128.39 (CH), 127.21 (CH), 48.79 (C), 42.75 (CH2), 42.65
(CH2), 41.56 (CH2). Anal. calcd for C14H15N7Cl2O2S: C,
40.39; H, 3.63; N, 23.55. Found: C, 40.10; H: 3.80; N, 23.36.
2.1.5.5. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-(3,4-dichloro-
benzyl)sulfamide (17). Yield: 40%. MP (C): 192–197. 1H
NMR (DMSO-d6) d: 8.15 (s, 1H, CH), 8.07 (s, 1H, CH), 7.56
Adenine and benzimidazole-based mimics of REP-3123 as antibacterial agents 201(m, 3H, 2  CH-Ar + NH), 7.26 (m, 2H, CH-Ar + NH), 7.19
(s, 2H, NH2), 4.25 (m, 2H, CH2), 3.89 (s, 2H, CH2), 3.29 (m,
2H, CH2).
13C NMR (DMSO-d6) d: 155.91 (C), 152.33 (CH),
149.51 (C), 141.09 (CH), 139.66 (C), 130.76 (C), 130.32 (CH),
129.50 (C), 129.43 (CH), 127.83 (CH), 118.75 (C), 44.38
(CH2), 42.81 (CH2), 41.54 (CH2). HRMS m/z (EI): Calcd for
416.0458 [M+H]+, Found: 416.0453 [M+H]+.
2.1.5.6. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-(4-ﬂuoroben-
zyl)sulfamide (18). Yield: 67%. MP (C): 136–140. 1H NMR
(DMSO-d6) d: 8.16 (s, 1H, CH), 8.07 (s, 1H, CH), 7.44 (t,
J= 6.25, 1H, NH), 7.29 (m, 2H, CH-Ar), 7.21 (m, 3H, NH
+NH2), 7.12 (t, J= 8.8, 2H, CH-Ar), 4.26 (t, J= 6.0, 2H,
CH2), 3.86 (d, J= 6.2, 2H, CH2), 3.28 (q, J= 5.9, 2H,
CH2).
13C NMR (DMSO-d6) d: 162.23 (C), 160.30 (C),
155.93 (C), 152.32 (CH), 149.51 (C), 141.09 (CH), 134.38
(C), 129.60 (CH), 129.53 (CH), 118.77 (C), 114.95 (CH),
114.78 (CH), 44.88 (CH2), 42.76 (CH2), 41.56 (CH2). HRMS
m/z (EI): Calcd for 365.1070 [M]+, Found: 365.1073 [M]+.
2.1.5.7. N-[2-(6-amino-9H-purin-9-yl)-ethyl]-N0-(4-cyanoben-
zyl)sulfamide (19). Yield: 59.5%. MP (C): 202–206. 1H NMR
(DMSO-d6) d: 8.16 (s, 1H, CH), 8.07 (s, 1H, CH), 7.78 (d,
J= 7.8, 2H, CH-Ar), 7.59 (bs, 1H, NH), 7.47 (d, J= 7.6,
2H, CH-Ar), 7.27 (bs, 1H, NH), 7.20 (bs, 2H, NH2), 4.25
(app.s, 2H, CH2), 3.97 (d, J= 5.1, 2H, CH2), 3.29 (app. d,
J= 5.0, 2H, CH2).
13C NMR (DMSO-d6) d: 155.94 (C),
152.33 (CH), 149.52 (C), 144.29 (C), 141.08 (CH), 132.12
(2  CH), 128.30 (2  CH), 118.82 (C), 118.78 (C), 109.74
(C), 45.14 (CH2), 42.78 (CH2), 41.55 (CH2). HRMS m/z
(EI): Calcd for 372.1117 [M]+, Found: 372.1114 [M]+.
2.1.5.8. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-benzylsulfamide
(20). Yield: 82%. MP (C): 181–186. 1H NMR (DMSO-d6) d:
8.17 (s, 1H, CH-Imidazole), 7.67 (d, J= 7.9, 1H, CH-Ar), 7.62
(d, J= 8.0, 1H, CH-Ar), 7.46 (t, J= 6.1, 1H, NH), 7.2 (m,
8H, 7  CH-Ar + NH), 4.3 (t, J= 6.0, 2H, CH2), 3.8 (d,
J= 6.1, 2H, CH2), 3.2 (m, 2H, CH2).
13C NMR (DMSO-d6)
d: 144.24 (CH-Imidazole), 143.43 (C), 138.14 (C), 133.83 (C),
128.16 (2  CH), 127.62 (CH), 127.00 (CH), 122.25 (CH),
121.44 (CH), 119.40 (2  CH), 110.37 (CH), 45.59 (CH2),
43.71 (CH2), 41.89 (CH2). HRMS m/z (EI): Calcd: 331.1223
[M+H]+, Found: 331.1227 [M+H]+.
2.1.5.9. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(4-methoxyben-
zyl)sulfamide (21). Yield: 61%. MP (C): 180–184. 1H NMR
(DMSO-d6) d: 8.18 (s, 1H, CH-Imidazole), 7.67 (d, J= 7.90,
1H, CH-Ar), 7.62 (d, J= 8.0, 1H, CH-Ar), 7.35 (t, J= 6.1,
1H, NH), 7.28 (wt, J= 7.1, 7.8, 1H, CH-Ar), 7.23 (m,1H,
CH-Ar), 7.17 (t, J= 5.9, 1H, NH), 7.13 (d, J= 8.5, 2H,
2  CH-Ar), 6.85 (d, J= 8.6, 2H, 2  CH-Ar), 4.35 (t,
J= 6.1, 2H,CH2), 3.73 (d, J= 5.95, 2H, CH2), 3.72 (s, 3H,
OCH3), 3.2 (q, J= 5.65, 2H, CH2).
13C NMR (DMSO-d6)
d: 158.36 (C), 144.22 (CH-Imidazole), 143.41 (C), 133.83 (C),
129.99 (C), 128.16 (2  CH), 122.24 (CH), 121.43 (CH),
119.40 (CH), 113.57 (2  CH), 110.35 (CH), 55.03 (CH3)
45.11 (CH2), 43.69 (CH2), 41.88 (CH2). Anal. calcd for
C17H20N4O3S: C, 56.65; H, 5.59; N, 15.54. Found: C, 56.96;
H, 5.58; N, 15.33.
2.1.5.10. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(3-chloroben-
zyl)sulfamide (22). Yield: 69%. MP (C): 162–166. 1H NMR(DMSO-d6) d: 8.18 (s, 1H, CH-Imidazole), 7.67 (d, J= 8.0,
1H, CH-Ar), 7.62 (d, J= 8.0, 1H, CH-Ar), 7.53 (t, J= 6.3,
1H, NH), 7.25 (m, 7H, 6  CH-Ar + NH), 4.36 (t, J= 6.1,
2H, CH2), 3.79 (d, J= 6.1, 2H, CH2), 3.26 (q, J= 6.0, 2H,
CH2).
13C NMR (DMSO-d6) d: 144.24 (CH-Imidazole),
143.42 (C), 140.88 (C), 133.83 (C), 132.85 (C), 130.03 (CH),
127.32 (CH), 126.92 (CH), 126.17 (CH), 122.26 (CH), 121.45
(CH), 119.39 (CH), 110.35 (CH), 44.89 (CH2), 43.72 (CH2),
41.89 (CH2). Anal. calcd for C16H17ClN4O2S: C, 52.67; H,
4.70; N, 15.35. Found: C, 52.74; H, 4.79; N, 15.22.
2.1.5.11. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(2,4-dichloro-
benzyl) sulfamide (23). Yield: 64%. MP (C): 158–162. 1H
NMR (DMSO-d6) d: 8.17 (s, 1H, CH-Imidazole), 7.65 (d,
J= 7.9, 1H, CH-Ar), 7.61 (d, J= 8.0, 1H, CH-Ar), 7.55 (m,
2H, NH+ CH-Ar), 7.41 (m, 2H, 2  CH-Ar), 7.32 (t,
J= 5.9, 1H, NH), 7.27 (t, J= 7.5, 1H, CH-Ar), 7.21 (t,
J= 7.5, 1H, CH-Ar), 4.36 (t, J= 6.1, 2H, CH2), 3.91 (d,
J= 6.1, 2H, CH2), 3.27 (q, J= 6.0, 2H, CH2).
13C NMR
(DMSO-d6) d: 144.18 (CH-Imidazole), 143.38 (C), 134.71
(C), 133.80 (C), 132.91 (C), 132.40 (C), 130.79 (CH), 128.41
(CH), 127.20 (CH), 122.24 (CH), 121.42 (CH), 119.41 (CH),
110.29 (CH), 43.72 (CH2), 42.80 (CH2), 41.90 (CH2). Anal.
calcd for C16H16Cl2N4O2S: C, 48.13; H, 4.04; N, 14.02. Found:
C, 47.98; H, 4.06; N, 14.14.
2.1.5.12. N-[2-(1H-Benzimidazol-1-yl)ethyl]-N0-(3,4-dichloro-
benzyl)sulfamide (24). Yield: 71%. MP (C): 164–169. 1H
NMR (DMSO-d6) d: 8.17 (s, 1H, CH-imidazole), 7.67 (d,
J= 8.0, 1H, CH-Ar), 7.62 (d, J= 8.0, 1H, CH-Ar), 7.51 (m,
1H, CH-Ar), 7.46 (s, 1H, CH-Ar), 7.2 (m, 5H, 3  CH-Ar,
2  NH, D2O-exchangeable), 4.3 (t, J= 6.0, 2H, CH2), 3.7
(d, J= 6.0, 2H, CH2), 3.2 (q, J= 5.6, 2H, CH2).
13C NMR
(DMSO-d6) d: 144.25 (CH-imidazole), 143.41 (C), 139.61
(C), 133.81 (C), 130.75 (C), 130.32 (CH), 129.50 (C), 129.42
(CH), 127.81 (CH), 122.26 (CH), 121.44 (CH), 119.39 (CH),
110.33 (CH), 44.51 (CH2), 44.31 (CH2), 43.72 (CH2). HRMS
m/z (EI): calcd for 399.0449 [M+H]+, Found: 399.0446 [M
+H]+.
2.1.5.13. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(4-ﬂuoroben-
zyl)sulfamide (25). Yield: 80%. MP (C): 176–180. 1H NMR
(DMSO-d6) d: 8.19 (s, 1H, CH-imidazole), 7.66 (d, J= 7.9,
1H, CH-Ar), 7.62 (d, J= 8.0, 1H, CH-Ar), 7.49 (t, J= 6.4,
1H, CH-Ar), 7.25 (m, 5H), 7.11 (m, 2H), 4.36 (t, J= 6.0,
2H, CH2), 3.74 (d, J= 6.3, 2H, CH2), 3.23 (q, J= 6.0, 2H,
CH2).
13C NMR (DMSO-d6) d: 162.21 (C), 160.28 (C),
144.27 (CH), 143.36 (C), 134.34 (C), 133.79 (C), 129.60
(CH), 129.54 (CH), 122.27 (CH), 121.46 (CH), 119.38 (CH),
114.98 (CH), 114.81 (CH), 110.38 (CH), 44.77 (CH2), 43.67
(CH2), 41.86 (CH2). HRMS (EI): Calcd for 349.1135 [M
+H]+, Found: 349.1136 [M+H]+.2.1.6. General procedure for the synthesis of N-[2-(adenyl- or
benzimidazolyl)ethyl]-N0-(un)substitutedbenzylureas or
thioureas (26–33)
To a solution of 9-(2-aminoethyl)-9H-purin-6-amine trifluo-
roacetate (5; 1.2 eq.) or 2-(1H-benzimidazol-1-yl)ethanamine
trifluoroacetate (6; 1.2 eq.) in anhydrous acetonitrile (10 mL),
was added triethylamine (2.4 eq.) followed by a solution of
the appropriate benzylisocyanate (1 eq.) in anhydrous
202 A.G. Eissa et al.acetonitrile (5 mL) while cooling at 0 C (ice bath). After
30 min the reaction was stirred at 60 C overnight. The reac-
tion mixture was cooled to room temperature and stirred for
2 h. The suspension obtained was filtered and the precipitate
was washed with water. The residue was dissolved in ethyl
acetate (100 mL) and washed with H2O (3  50 mL). The
organic layer was dried over MgSO4 and evaporated under
vacuum. The residue was saturated with diethyl ether and stir-
red for 2 h. The suspension obtained was filtered and the pre-
cipitate was washed with water to provide the title compounds
as white solids.
2.1.6.1. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-benzyl urea
(26). Yield: 71%. MP (C): 212–216. 1H NMR (DMSO-d6)
d: 8.15 (s, 1H, CH-adenine), 8.02 (s, 1H, CH-adenine), 7.20
(m, 7H, CH-Ar + NH2), 6.38 (t, J= 5.7, 1H, NH), 6.09 (t,
J= 5.5, 1H, NH), 4.20 (m, 4H, 2  CH2), 3.48 (q, J= 5.5,
2H, CH2).
13C NMR (DMSO-d6) d: 157.89 (C), 155.92 (C),
152.30 (CH-adenine), 149.67 (C), 140.91 (CH-adenine),
140.76 (C), 128.14 (2  CH-Ar), 126.88 (2  CH-Ar), 126.46
(CH-Ar), 118.77 (C), 43.48 (CH2), 42.82 (CH2), CH2 signal
is obscured by DMSO-d6 signal (39.01–39.85). HRMS m/z
(EI): calcd for 312.1567 [M+H]+, Found: 312.1565 [M+H]+.
2.1.6.2. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-(4-methoxy-
benzyl) urea (27). Yield: 91%. MP (C): 206–210. 1H NMR
(DMSO-d6) d: 8.14 (s, 1H, CH-adenine), 8.02 (s, 1H, CH-
adenine), 7.21 (bs, 2H, NH2), 7.1 (d, J= 8.4, 2H, CH-Ar),
6.85 (d, J= 8.5, 2H, CH-Ar), 6.30 (t, J= 5.6, 1H, NH),
6.05 (t, J= 5.0, 1H, NH), 4.18 (t, J= 5.75, 2H, CH2), 4.09
(d, J= 5.8, 2H, CH2), 3.72 (s, 3H, OCH3), 3.47 (q, J= 5.7,
2H, CH2).
13C NMR (DMSO-d6) d: 157.98 (C), 157.84 (C),
155.90 (C), 152.30 (CH), 149.62 (C), 140.93 (CH), 132.62
(C), 128.18 (2  CH), 118.70 (C), 113.54 (2  CH), 55.00
(CH3), 43.48 (CH2), 42.24 (CH2), CH2 signal is obscured by
DMSO-d6 signal (39.94–38.98). Anal. calcd for C16H19N7O2:
C, 56.30; H: 5.61; N, 28.71. Found: C, 55.92; H, 5.62; N, 28.53.
2.1.6.3. N-[2-(6-amino-9H-purin-9-yl)ethyl]-N0-(2,4-dichloro-
benzyl)urea (28). Yield: 80%. MP (C): 228–232. 1H NMR
(DMSO-d6) d: 8.14 (s, 1H, CH-adenine), 8.03 (s, 1H, CH-
adenine), 7.5 (d, J= 2.1, 1H, CH-Ar), 7.39 (dd, J= 2.0, 8.4,
1H, CH-Ar), 7.19 (d, J= 8.4, 1H, CH-Ar), 7.13 (bs, 2H,
NH2), 6.46 (t, J= 5.9, 1H, NH), 6.25 (t, J= 5.8, 1H, NH),
4.19 (m, 4H, 2  CH2), 3.47 (q, J= 5.6, 2H, CH2). 13C
NMR (DMSO-d6) d: 157.74 (C), 155.88 (C), 152.30 (CH),
149.65 (C), 140.98 (CH), 136.99 (C), 132.51 (C), 131.79 (C),
129.71 (CH), 128.32 (CH), 127.17 (CH), 118.70 (C), 43.41
(CH2), 40.34 (CH2), CH2 signal is obscured by DMSO-d6 sig-
nal (39.94–38.94). Anal. calcd for C15H15Cl2N7O: C, 47.38; H,
3.98; N, 25.79. Found: C, 47.11; H, 3.73; N, 25.79.
2.1.6.4. N-[2-(1H-Benzimidazol-1-yl)ethyl]-N0-benzyl urea
(29). Yield: 75%. MP (C): 158–162. 1H NMR (DMSO-d6)
d: 8.14 (s, 1H, CH-imidazole), 7.66 (d, J= 7.6, 1H, CH-Ar),
7.60 (d, J= 7.7, 1H, CH-Ar), 7.25 (m, 7H, CH-Ar), 6.47 (t,
J= 5.8, 1H, NH), 6.16 (t, J= 5.4 Hz, 1H, NH), 4.30 (t,
J= 6.0, 2H, CH2), 4.20 (d, J= 5.9, 2H, CH2), 3.45 (dd,
J= 6.0, 11.9, 2H, CH2).
13C NMR (DMSO-d6) d: 158.00
(C), 144.05 (CH-imidazole), 143.40 (C), 140.77 (C), 134.02
(C), 128.16 (2  CH), 126.94 (2  CH), 126.49 (CH), 122.17(CH), 121.34 (CH), 119.34 (CH), 110.34 (CH), 44.39 (CH2),
42.82 (CH2), CH2 signal is obscured by DMSO-d6 signal
(39.01–39.85). HRMS m/z (EI): clacd for 295.1553 [M+H]+,
Found: 295.1557 [M+H]+.
2.1.6.5. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(4-methoxyben-
zyl)urea (30). Yield: 43%. MP (C): 124–128. 1H NMR
(DMSO-d6) d: 8.13 (s, 1H, CH-imidazole), 7.66 (d, J= 7.4,
1H, CH-Ar), 7.60 (d, J= 7.6, 1H, CH-Ar), 7.22 (m, 2H,
CH-Ar), 7.13 (d, J= 8.6, 2H, CH-Ar), 6.86 (m, 2H, CH-
Ar), 6.34 (t, J= 5.8, 1H, NH), 6.05 (t, J= 5.7, 1H, NH),
4.29 (t, J= 6.0, 2H, CH2), 4.12 (d, J= 5.9, 2H, CH2), 3.73
(s, 3H, OCH3), 3.43 (q, J= 6.0, 2H, CH2).
13C NMR
(DMSO-d6) d: 158.02 (C), 157.92 (C), 144.06 (CH-
imidazole), 143.38 (C), 133.99 (C), 132.63 (C), 128.16
(2  CH), 122.19 (CH), 121.36 (CH), 119.34 (CH), 113.57
(2  CH), 110.35 (CH), 55.00 (CH3), 44.40 (CH2), 42.39
(CH2), CH2 signal is obscured by DMSO-d6 signal (39.95–
38.95). Anal. calcd for C18H20N4O2: C, 66.65; H: 6.21; N,
17.26. Found: C, 66.62; H, 6.19; N, 16.91.
2.1.6.6. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-(2,4-dichloro-
benzyl)urea (31). Yield: 64%. MP (C): 148–152. 1H NMR
(DMSO-d6) d: 8.14 (s, 1H, CH-imidazole), 7.66 (d, J= 7.5,
1H, CH-Ar), 7.59 (d, J= 7.8, 1H, CH-Ar), 7.56 (d, J= 2.0,
1H, CH-Ar), 7.39 (dd, J= 2.0, 8.3, 1H, CH-Ar), 7.22 (m,
3H, CH-Ar), 6.50 (t, J= 5.9, 1H, NH), 6.25 (t, J= 5.6 Hz,
1H, NH), 4.30 (t, J= 6.0, 2H, CH2), 4.22 (d, J= 5.9, 2H,
CH2), 3.45 (q, J= 5.9, 11.9, 2H, CH2).
13C NMR (DMSO-
d6) d: 157.81 (C), 144.07 (CH-imidazole), 143.36 (C), 136.99
(C), 133.99 (C), 132.61 (C), 131.82 (C), 129.92 (CH), 128.43
(CH), 127.23 (CH), 122.19 (CH), 121.38 (CH), 119.34 (CH),
110.31 (CH), 44.35 (CH2), 40.50 (CH2), CH2 signal is obscured
by DMSO-d6 signal (39.98–39.98). Anal. calcd for C17H16Cl2-
N4O0.2 H2O: C, 55.66; H, 4.50; N, 15.27. Found: C, 55.46; H,
4.33; N, 14.96.
2.1.6.7. N-[2-(6-Amino-9H-purin-9-yl)ethyl]-N0-benzyl thiourea
(32). Yield: 75%. MP (C): 176–182. 1H NMR (DMSO-d6) d:
8.15 (s, 1H, CH), 8.01 (s, 1H, CH), 7.94 (bs, 1H, NH), 7.60 (bs,
1H, NH), 7.32 (t, J= 7.3, 2H, CH-Ar), 7.23 (m, 3H, CH-Ar),
7.19 (bs, 2H, NH2), 4.64 (app.s, 2H, CH2), 4.34 (app.s, 2H,
CH2), 3.90 (app.s, 2H, CH2).
13C NMR (DMSO-d6) d:
155.93 (C), 152.33 (CH), 149.67 (C), 140.81 (CH), 139.14
(C), 128.20 (2  CH), 127.11 (2  CH), 126.75 (CH), 118.76
(C), 42.47 (CH2), 2  CH2 signals are obscured by DMSO-d6
signal (40.01–39.01). HRMS m/z (EI): calcd for 328.1339 [M
+H]+, Found: 328.1339 [M+H]+.
2.1.6.8. N-[2-(1H-benzimidazol-1-yl)ethyl]-N0-benzyl thiourea
(33). Yield: 93%. MP (C): 158–162. 1H NMR (DMSO-d6) d:
8.14 (s, 1H, CH-imidazole), 7.95 (bs, 1H, NH), 7.66 (wt,
J= 7.1, 5.8, 2H, CH-Ar), 7.57 (bs, 1H, NH), 7.33 (wt,
J= 7.9, 7.0, 2H-Ar), 7.26 (m, 5H, CH-Ar), 4.66 (app.s., 2H,
CH2), 4.47 (t, J= 6.0, 2H, CH2), 3.87 (app.s., 2H, CH2).
13C NMR (DMSO-d6) d: 143.85 (CH), 142.73 (C), 133.88
(C), 128.27 (2  CH), 127.06 (2  CH), 126.90 (CH), 122.57
(CH), 121.76 (CH), 119.20 (CH), 110.36 (CH), 43.25 (CH2),
2 CH2 signals are obscured by DMSO-d6 signal (39.47–
38.45). HRMS m/z (EI): calcd for 311.1325 [M+H]+, Found:
311.1325 [M+H]+.
Figure 2 Adenine-based sulfamide (18) sitting in C. difﬁcile
methionyl-tRNA synthetase two active site pockets.
Adenine and benzimidazole-based mimics of REP-3123 as antibacterial agents 2032.1.7. 2-(6-amino-9H-purin-9-yl)ethanol (34)
Adenine (3) (5.60 g, 41.4 mmol), ethylene carbonate (4 g,
45.4 mmol), and a trace of sodium hydroxide were dissolved
in anhydrous DMF (45 mL). The reaction mixture was
refluxed for 3.5 h. then left stirring overnight at room temper-
ature. The solvent was removed under vacuum and the residue
recrystallized from methanol to afford [2-(6-amino-9H-purin-
9-yl)ethanol] (13) as a white solid.
Yield: 70%. MP (C): 240–242 C (lit. 238.3–240.4).23 1H
NMR (DMSO-d6): d 8.15 (s, 1H, CH), 8.09 (s, 1H, CH),
7.20 (bs, 2H, NH2), 5.02 (t, J= 5.4, 1H, OH), 4.20 (t,
J= 5.5, 2H, CH2), 3.75 (q, J= 5.4, 2H, CH2). The product
was used in the next step without further characterization.
2.1.8. 2-(6-amino-9H-purin-9-yl)ethyl methanesulfonate (35)
To a solution of 2-(6-amino-9H-purin-9-yl)ethanol (34; 4.94 g,
27.6 mmol) in dry pyridine (76 mL) cooled to 0 C, methane-
sulfonyl chloride (2.35 mL, 30.3 mmol) was added. After
10 min the reaction was allowed to warm to room temperature.
After 1 h, pyridine was evaporated and the residue dissolved in
water (100 mL). The aqueous solution was extracted with ethyl
acetate (3  100 mL). The combined organic extracts were
dried with MgSO4 and filtered. The solvent was removed under
vacuum and remaining pyridine was removed by adding
toluene to form an azeotropic mixture which was then
removed under vacuum. 2-(6-amino-9H-purin-9-yl)ethyl
methanesulfonate (14) was obtained as a white solid.
Yield: 51%. MP (C): 186–190 (lit. 189–192).24 1H NMR
(DMSO-d6): d 8.17 (s, 1H, CH), 8.15 (s, 1H, CH), 7.26 (bs,
2H, NH2), 4.61 (t, J= 5.2, 2H, CH2), 4.51 (t, J= 5.1, 2H,




To a solution of N-benzyl ethylene diamine (0.59 g,
3.92 mmol) in ethanol (40 mL) was added methanesulfonic
acid 2-(6-amino-purin-9-yl)ethyl ester (35; 0.4 g, 1.57 mmol).
The reaction mixture was refluxed for 3 days at 80 C. The sol-
vent was removed under vacuum to afford the crude product
as a yellowish white solid which was dissolved in methanol
and the solution was treated with triethylamine (0.6 g,
6.0 mmol) and di-tert-butyl dicarbonate (1.31 g, 6.0 mmol).
The reaction mixture was refluxed for 1 h then stirred at room
temperature overnight. The solvent was removed under vac-
uum and the residue dissolved in dichloromethane (50 mL)
then washed with 1 N HCl (2  20 mL) and brine
(2  20 mL). The organic layer was dried over MgSO4 and
evaporated under vacuum. The residue was saturated with
diethyl ether and stirred for 2 h then the resulting suspension
was filtered to afford the BOC protected intermediate as a
white solid. A solution of the crude product in trifluoroacetic
acid/dichloromethane (20 mL,75:25 v/v) was stirred overnight
at room temperature. The solvent was then co-evaporated with
ethanol several times. The residue was saturated with diethyl
ether (75 mL), stirred for 2 h to give the title compound as a
white solid collected by filtration.
Overall yield: 11%. MP (C): 178–181. 1H NMR (CD3OD)
d: 8.25 (s, 1H, CH-Adenine), 8.22 (s, 1H, CH-Adenine), 7.51–
7.46 (m, 5H, CH-Ar), 4.57 (t, J= 5.7, 2H, CH2), 4.25 (s, 2H,
CH2), 3.48 (t, J= 5.7, 2H, CH2), (2  CH2) peaks wereobscured under CD3OD peak.
13C NMR (CD3OD) d: 155.77
(C), 151.26 (CH), 150.86 (C), 143.65 (CH), 132.43 (C),
130.97 (2  CH), 130.82 (CH), 130.37 (2  CH), 120.10 (C),
52.48 (CH2), 45.40 (CH2), 45.12 (CH2), 43.17 (CH2), CH2 sig-
nal was obscured under CD3OD signals (50.39–48.51). HRMS
m/z (EI): Calcd for 652.1566 [MH], Found: 652.1566
[MH].
2.2. Microbiological assays
2.2.1. In vitro antibacterial activity against C. difﬁcile strain
1813
Frozen stocks of C. difﬁcile 1813 strain were thawed and
streaked for purity on pre-prepared fastidious anaerobe agar
plates and incubated at 37 C for 48 h in an anaerobic cabinet
(A95 Workstation, Don Whitley Ltd., UK). The gas mixture
of the cabinet was composed of 10% CO2, 10% H2 and
80% N2 as recommend by the CLSI (2003). Post incubation,
plates were inspected for purity and visible CFUs were added
to 3 mL of sterile brain heart infusion broth (BHI) using a
10 lL inoculation loop to give the broth turbidity equal to a
McFarland standard of 1 (108 cfu/mL). To ensure that sus-
pensions of cultures with turbidity equal to a McFarland stan-
dard of 1 approximately contained 1  108 cfu/mL, viable
counts were performed on strain 1813 using the Miles and
Misra method.25 McFarland turbidity standards were used
to standardize cultures to all concentrations. A stock solution
of each compound (256 lg/mL) was prepared. The method
used plates for each concentration of bacteria (106, 105, 104,
103, 102 and 101). For each concentration of bacteria, doubling
dilutions of compounds were used from the highest concentra-
tion 85.33 lg/mL down to 0.33 lg/mL. Finally, controls con-
sisted of Vancomycin at 12 lg/mL – complete inhibition (of
all strains)/Metronidazole at 8 lg/mL – complete inhibition
(of all strains). In addition, a control of broth and 20% DMSO
– no inhibition of growth, broth and water – no inhibition of
growth, broth only - no inhibition of growth.
2.2.2. In vitro antibacterial activity against B. anthracis
B. anthracis was grown overnight at 37 C within brain heart
infusion (BHI) broth with shaking at 250 rpm. Again the con-
centration of bacteria was confirmed by the Miles and Misra
Figure 3 2D ligand interaction between sulfamide derivative 18
and the C. difﬁcilemethionyl-tRNA synthetase active site residues.
204 A.G. Eissa et al.drop count and McFarland standard. For this test a single
concentration of bacteria was used 1  104 cfu/mL. Different
volumes of the stock solution of test compounds (256 lg/
mL) were put in separate wells, diluted with an adequate
amount of distilled water, mixed with 100 lL of BHI broth
and 50 lL of B. anthracis (1  104 cfu/mL) to give 8 different
final concentrations of the compounds: 102.4 lg/mL,





























Scheme 1 Reagents and conditions: (a) Benzimidazole or adenine, K
temperature, overnight. (c) DCM, 0–10 C, 1 h. (d) Substituted be
acetonitrile, 90 C, overnight.
Figure 4 Compound (18) docked in the flipped position into C51.2 lg/mL, 40.96 lg/mL, and 30.72 lg/mL. Growth was then
measured using a plate reader (Infinitie F2000 Pro) for 24 h
with absorbance readings being taken at 595 nm every 5 min.
Controls consisted of 12 lg/mL of ciprofloxacin, 20% DMSO
diluted in the same way as the test solutions and BHI broth
with bacteria only at 1  104 cfu/mL. Results were interpreted
by comparison to the bacteria alone in BHI broth and inhibi-
tion could be observed by no increase in absorbance.3. Results and discussion
3.1. Chemistry
The synthetic routes for the designed target compounds are
illustrated in Schemes 1–3. The BOC-protected heteroaryl ethy-
lamines (2,3) were prepared following reported procedures21
through treatment of benzimidazole or adenine with tert-butyl
(2-bromoethyl)carbamate (1) in the presence of potassium
carbonate and 18-crown-6. BOC deprotection was effected by
trifluoroacetic acid to afford the intermediate heteroaryl ethy-
lamines (4,5) as the trifluoroacetate salts in almost quantitative
yields. On the other hand, the sulfamoylating intermediates,
N-sulfamoyloxazolidinones (6–12), were prepared following a























2CO3, 18-crown-6, DMF, 60 C, overnight. (b) TFA/DCM, room
nzylamines, TEA, DCM, 0 C to room temperature. (e) TEA,


























































Scheme 3 Reagents and conditions: (a) Ethylene carbonate,
NaOH, DMF, reflux, 3.5 h then room temperature, overnight. (b)
Mesyl chloride, pyridine, 0 C to room temperature, 1 h. (c) N-
benzyl ethylenediamine, ethanol, 80 C, 3 days. (d) Di-tert-butyl
dicarbonate, TEA, methanol, reflux, 1 h then room temperature,
overnight. (e) TFA, DCM, room temperature, overnight.
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benzylamines in the presence of trimethylamine under nitrogen
atmosphere as shown in Scheme 1. Sulfamoylation of the het-
eroaryl ethylamines (4,5) with the intermediates (6–12) under
basic conditions of trimethylamine afforded the target sul-
famides (13–25) in fairly good yields. In 1H NMR spectra of
the adenine-based sulfamides, two characteristic downfield sin-
glets appeared at 8.15–8.16 and 8.06–8.07 ppm corresponding
to adenine ring protons at C-8 and C-2, respectively. In case
of the benzimidazole-based sulfamides, however, ring proton
at C-2 apparently appeared more downfield (8.17–8.19 ppm)
as compared to other ring protons. The sulfamide protons con-
sistently appeared at 7.17–7.59 ppmwithin the aromatic region.
In 13C NMR spectra, the right number of carbon atoms
appeared at their expected chemical shifts. In Scheme 2, the
key intermediate heteroaryl ethylamines (6–12) were treated
with substituted benzylisocyanates or benzylisothiocyanates
under basic conditions to give the desired ureas and thioureas
(26–33) in good yields. Finally, the target diamine compound
(36) was obtained in three steps as illustrated in Scheme 3.
Hydroxyethylation of adenine was achieved in 70% yield using
ethylene carbonate in the presence of traces of sodium hydrox-
ide.23 The hydroxyethyl adenine (34) was mesylated under basic
conditions of pyridine to afford the intermediate (35)24 which
was reacted withN-benzyl ethylene diamine to give the final dia-
mine (36) in low overall yield due to chemical purification
through BOC protection and deprotection. 1H and 13C NMR
spectra of the target ureas, thioureas (26–33) as well as the targetdiamine (36) showed similar patterns to their sulfamide counter-
parts. Structures of all the synthesized compounds were charac-
terized by means of 1H NMR, 13C NMR spectral data and
purity of the final target compounds was confirmed by High
Resolution Mass Spectroscopy or microanalysis. Docking
interactions of the target compounds were performed using
Molecular Operating Environment (MOE).26 The target
adenine-based sulfamide (18) was found to have reasonable
docking result based on both visual inspection of the pose and
the docking score. Compound (18) fitted well in the two pockets
previously observed forREP-312317 with different hydrophobic
and hydrogen bonding interactions (Fig. 2). Lys56, Glu262,
Glu55, Lys59 and Ile12 were found to be the main interactions
for this compound (Fig. 3). In addition, compound (18)
docked in the flipped position with the same key interactions
(Fig. 4).
3.2. Biological evaluation
Out of twenty-two compounds synthesized, only sixteen were
available for biological testing due to insufficient solubility in
DMSO under the assay conditions. The other six compounds,
namely, 22–25, 28 and 31, precipitated on dilution to 20%
DMSO with distilled water. Most of the inadequately soluble
compounds were benzimidazole-based and chloro substituted.
Compounds with adequate solubility in DMSO were tested
against C. difﬁcile strain 1813 and B. anthracis. The minimum
inhibitory concentration (MIC) for the test compounds was
determined by the microdilution method in brain heart infu-
sion (BHI) broth. Reference drugs in the assays were metron-
idazole and vancomycin for C. difﬁcile and ciprofloxacin for B.
anthracis. Among the compounds tested, only the adenine-
based sulfamide (18) showed activity against C. difﬁcile with
an MIC of 85.33 lg/mL. Against B. anthracis, however, all
the tested adenine-based sulfamides, with the exception of
the cyano substituted derivative (19), and the benzimidazole-
based sulfamides (20, 21) displayed activity with an MIC of
102.4 lg/mL. On the other hand, only the benzimidazole
derivative (29) was active (MIC = 102.4 lg/mL) among the
ureas in both series. The thioureas (32, 33) exhibited more
promising activity with the adenine-based derivative (32)
slightly more potent (MIC = 92.16 lg/mL) than the benzimi-
dazole counterpart (33; MIC = 102.4 lg/mL). Finally, the
adenine-based diamine (36) showed equal activity to its
thiourea analogue (32) with an MIC of 92.16 lg/mL. Biologi-
cal results are summarized in Table 1. In summary, the
adenine-based analogues were, in general, better antibacterial
agents as compared to their benzimidazole-based counterparts.
The adenine-based sulfamide (18) was the only target









Cpd Het. X R1 R2 R3 MIC (lg/ml)
C. diﬃcile-1813 B. anthracis
13 Adenine SO2 H H H a 102.4
14 Adenine SO2 H H OCH3 a 102.4
15 Adenine SO2 H Cl H a 102.4
16 Adenine SO2 Cl H Cl a 102.4
17 Adenine SO2 Cl Cl H a 102.4
18 Adenine SO2 H H F 85.33 102.4
19 Adenine SO2 H Cl CN a a
20 Benzimidazole SO2 H H H a 102.4
21 Benzimidazole SO2 H H OCH3 a 102.4
22 Benzimidazole SO2 H Cl H b b
23 Benzimidazole SO2 Cl H Cl b b
24 Benzimidazole SO2 Cl Cl H b b
25 Benzimidazole SO2 H H F b b
26 Adenine C‚O H H H a a
27 Adenine C‚O H H OCH3 a a
28 Adenine C‚O Cl H Cl b b
29 Benzimidazole C‚O H H H a 102.4
30 Benzimidazole C‚O H H OCH3 a a
31 Benzimidazole C‚O Cl H Cl b b
32 Adenine C‚S H H H a 92.16
33 Benzimidazole C‚S H H H a 102.4
36 Adenine Ethyl H H H a 92.16
aInactive; bNot tested.
206 A.G. Eissa et al.compound that displayed activity against both target organ-
isms. The thioureas can act as a better scaffold than the ureas
as evident from the biological results of the unsubstituted
thiourea (32) as compared to its unsubstituted urea counter-
part (26). In addition, the limited solubility of most of the ben-
zimidazoles directs us to focus on the adenine-based scaffold in
our currently underway investigation for structure
optimization.
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